Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLoans - Loss AllowanceLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Innate Pharma (IPHA) Non-Current Assets (2017 - 2025)

Historic Non-Current Assets for Innate Pharma (IPHA) over the last 9 years, with Q2 2025 value amounting to $31.6 million.

  • Innate Pharma's Non-Current Assets fell 2635.2% to $31.6 million in Q2 2025 from the same period last year, while for Jun 2025 it was $130.9 million, marking a year-over-year decrease of 3193.34%. This contributed to the annual value of $27.4 million for FY2024, which is 678.37% down from last year.
  • Innate Pharma's Non-Current Assets amounted to $31.6 million in Q2 2025, which was down 2635.2% from $27.1 million recorded in Q4 2024.
  • In the past 5 years, Innate Pharma's Non-Current Assets registered a high of $164.4 million during Q2 2021, and its lowest value of $27.1 million during Q4 2024.
  • For the 5-year period, Innate Pharma's Non-Current Assets averaged around $75.5 million, with its median value being $59.4 million (2023).
  • Data for Innate Pharma's Non-Current Assets shows a peak YoY increase of 744.08% (in 2021) and a maximum YoY decrease of 9990.29% (in 2021) over the last 5 years.
  • Quarter analysis of 5 years shows Innate Pharma's Non-Current Assets stood at $147.8 million in 2021, then crashed by 58.97% to $60.7 million in 2022, then crashed by 51.81% to $29.2 million in 2023, then fell by 7.47% to $27.1 million in 2024, then grew by 16.98% to $31.6 million in 2025.
  • Its Non-Current Assets stands at $31.6 million for Q2 2025, versus $27.1 million for Q4 2024 and $43.0 million for Q2 2024.